专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006022585A1 COMPOSITION AND METHOD FOR LONG-TERM GLYCEMIC CONTROL 审中-公开
标题翻译：用于长期糖化控制的组合物和方法
公开(公告)号：WO2006022585A1
公开(公告)日：2006-03-02
申请号：PCT/SE2005/001233
申请日：2005-08-24
申请人： METCON MEDICIN AB , LAKE, Mats , SMITH, Ulf
发明人： LAKE, Mats , SMITH, Ulf
IPC分类号： A61K31/718
CPC分类号： A61K31/718
摘要： Improved long-term control of blood glucose in a diabetic patient, the improvement measured as one of i) a lowering of the HbA1c value of said patient compared to the HbA1c value recorded before the treatment commences; ii) the stabilization of the HbA1c value at a value typical for patients with well-managed diabetes; iii) a lowering of the HbA1c value compared to a HbA1c value indicative of potentially harmful variations in blood glucose; or iv) a reduction of the incidence of nocturnal hypoglycemia, can be achieved by ingesting a therapeutic amount of starch at bedtime. A method and composition are disclosed.
摘要翻译：改善糖尿病患者血糖的长期控制，其改善作为i）与治疗开始前记录的HbA1c值相比降低所述患者的HbA1c值; ii）将HbA1c值稳定在具有良好管理的糖尿病患者的典型值; iii）与指示血糖的潜在有害变化的HbA1c值相比，降低HbA1c值; 或iv）夜间低血糖发生率的降低可以通过在睡前摄入治疗量的淀粉来实现。公开了一种方法和组合物。

2. 发明申请

WO2004024168A8 COMPOSITION AND METHOD FOR USE IN INTESTINAL CLEANSING PROCEDURES 审中-公开
标题翻译：用于肠道清洁程序的组合物和方法
公开(公告)号：WO2004024168A8
公开(公告)日：2004-12-09
申请号：PCT/SE0301428
申请日：2003-09-12
申请人： METCON MEDICIN AB , LAKE MATS , SMITH ULF , AXELSEN METTE , OLAUSSON EVA
发明人： LAKE MATS , SMITH ULF , AXELSEN METTE , OLAUSSON EVA
IPC分类号： A61K9/00 , A61K9/16 , A61K31/718 , A61K47/36 , A61P1/10 , A61P41/00
CPC分类号： A61K9/0095 , A61K9/1652 , A61K31/718 , A61K47/36
摘要： The nutritional deficiencies which constitute a serious side-effect of intestinal cleansing procedures can be alleviated or entirely avoided by a composition and method according to the present invention, wherein a complex carbohydrate is administered to the patient in a form and an amount which gives a blood glucose response similar to that following a normal meal, and stabilizes the blood glucose level above 3.5 mmol/l, preferably above about 4 mmol/l, thus preventing hypoglycaemia. The composition and method is suitable for all patients, but in particular for weakened, elderly or diabetic patients. The composition and method significantly improves the well-being of the patients, and does not reduce the cleansing effect achieved by conventional intestinal cleansing preparations or procedures, and has no known side effects. The preferred complex carbohydrate is native corn starch, and the composition may also include a simple carbohydrate, e.g. sucrose.
摘要翻译：构成肠清洁程序的严重副作用的营养缺陷可以通过根据本发明的组合物和方法来缓解或完全避免，其中复合碳水化合物以给予血液的形式和量施用于患者葡萄糖反应类似于正常进餐后的葡萄糖反应，并使血糖水平稳定在3.5mmol / l以上，优选高于约4mmol / l，从而防止低血糖。该组合物和方法适用于所有患者，但特别适用于虚弱，老年或糖尿病患者。该组合物和方法显着改善患者的健康，并且不降低常规肠道清洁制剂或程序所达到的清洁效果，并且没有已知的副作用。优选的复合碳水化合物是天然玉米淀粉，并且该组合物还可以包括简单的碳水化合物，蔗糖。

3. 发明申请

WO2004024168A1 COMPOSITION AND METHOD FOR USE IN INTESTINAL CLEANSING PROCEDURES 审中-公开
标题翻译：组合物和方法用于精华清洗程序
公开(公告)号：WO2004024168A1
公开(公告)日：2004-03-25
申请号：PCT/SE2003/001428
申请日：2003-09-12
申请人： METCON MEDICIN AB , LAKE, Mats , SMITH, Ulf , AXELSEN, Mette , OLAUSSON, Evan
发明人： LAKE, Mats , SMITH, Ulf , AXELSEN, Mette , OLAUSSON, Evan
IPC分类号： A61K31/718
CPC分类号： A61K9/0095 , A61K9/1652 , A61K31/718 , A61K47/36
摘要： The nutritional deficiencies which constitute a serious side-effect of intestinal cleansing procedures can be alleviated or entirely avoided by a composition and method according to the present invention, wherein a complex carbohydrate is administered to the patient in a form and an amount which gives a blood glucose response similar to that following a normal meal, and stabilizes the blood glucose level above 3.5 mmol/l, preferably above about 4 mmol/l, thus preventing hypoglycaemia. The composition and method is suitable for all patients, but in particular for weakened, elderly or diabetic patients. The composition and method significantly improves the well-being of the patients, and does not reduce the cleansing effect achieved by conventional intestinal cleansing preparations or procedures, and has no known side effects. The preferred complex carbohydrate is native corn starch, and the composition may also include a simple carbohydrate, e.g. sucrose.
摘要翻译：构成肠道清洁程序的严重副作用的营养缺乏可以通过根据本发明的组合物和方法来缓解或完全避免，其中将复合碳水化合物以给予血液的形式和量给予患者葡萄糖反应类似于正常膳食后的血糖反应，并且将血糖水平稳定在高于3.5mmol / l，优选高于约4mmol / l，从而预防低血糖。组合物和方法适用于所有患者，特别适用于弱化，老年或糖尿病患者。组合物和方法显着改善患者的健康，并且不会降低通过常规肠道清洁制剂或程序实现的清洁效果，并且没有已知的副作用。优选的复合碳水化合物是天然玉米淀粉，并且组合物还可以包括简单的碳水化合物，例如。蔗糖。

4. 发明申请

WO1992022311A1 NEW MEDICINAL USE OF IGF-II 审中-公开
标题翻译： IGF-II的新药物使用
公开(公告)号：WO1992022311A1
公开(公告)日：1992-12-23
申请号：PCT/SE1992000397
申请日：1992-06-11
申请人： KABI PHARMACIA AB , LAKE, Mats , JENNISCHE, Eva
发明人： KABI PHARMACIA AB
IPC分类号： A61K37/02
CPC分类号： A61K38/30 , Y10S424/13 , Y10S514/921
摘要： The use of IGF-II for preparing a medicament for the regeneration of muscle tissue; and methods for medical treatment for the purpose of regenerating muscle tissue, for minimizing scar formation during healing of a wound or for preventing undesired tissue adhesion after injury, such as after surgery.
摘要翻译：使用IGF-II制备用于再生肌肉组织的药物; 以及用于再生肌肉组织的目的的医疗处理方法，用于使伤口愈合期间的瘢痕形成最小化或者用于防止在损伤后例如手术后不期望的组织粘连。

5. 发明申请

WO1994013819A1 EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M 审中-公开
标题翻译：生产APOLIPOPROTEIN AI-M的表达系统
公开(公告)号：WO1994013819A1
公开(公告)日：1994-06-23
申请号：PCT/SE1993001061
申请日：1993-12-09
申请人： KABI PHARMACIA AB , ABRAHMSÉN, Lars , HOLMGREN, Erik , KALDERÉN, Christina , LAKE, Mats , MIKAELSSON, Åsa , SEJLITZ, Torsten
发明人： KABI PHARMACIA AB
IPC分类号： C12N15/70
CPC分类号： C07K14/775 , C07K2319/02 , C12N15/71
摘要： The invention relates to an expression system giving high extracellular production of apolipoprotein AI-M (Milano) using E. coli and comprises a plasmid carrying an origin of replication, an inducible promoter sequence, a DNA sequence coding for a signal peptide, a DNA sequence coding for apolipoprotein AI-M, and a transcription terminator. The invention also relates to a method of producing apolipoprotein AI-M using the expression system.
摘要翻译：本发明涉及使用大肠杆菌提供载脂蛋白AI-M（Milano）的高细胞外产生的表达系统，并且包含携带复制起点的质粒，诱导型启动子序列，编码信号肽的DNA序列，DNA序列编码载脂蛋白AI-M和转录终止子。本发明还涉及使用表达系统产生载脂蛋白AI-M的方法。

6. 发明申请

WO1993012143A1 DIMER OF MOLECULAR VARIANT OF APOLIPOPROTEIN AND PROCESSES FOR THE PRODUCTION THEREOF 审中-公开
标题翻译：亚油酸分子变体的二聚体及其生产方法
公开(公告)号：WO1993012143A1
公开(公告)日：1993-06-24
申请号：PCT/SE1992000858
申请日：1992-12-11
申请人： KABI PHARMACIA AB , CIRTORI, Cesare , FRANCESCHINI, Guido , ABRAHMSEN, Lars , HOLMGREN, Erik , LAKE, Mats , NILSSON, Björn , CHMIELEWSKA, Joanna
发明人： KABI PHARMACIA AB
IPC分类号： C07K15/16
CPC分类号： C07K14/775 , A61K38/1709 , Y02A50/473
摘要： The present invention relates to substantially pure dimers of Apolipoprotein Al-Milano, (Apo Al-M/Apo Al-M) which for the first time has been isolated and characterized from plasma. It also relates to pharmaceutical compositions comprising the Apo Al-M/Apo Al-M. Apolipoprotein Al-M dimer has been produced in a recombinant Escherichia coli system or collected from plasma from Apolipoprotein Al-Milano carriers. The invention also includes the method for the treatment of atherosclerosis and cardiovascular diseases and use of the dimer in the preparation of a medicament. The medicament containing the dimer can be used for treatment of atherosclerosis and cardiovascular diseases and prevention of thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.
摘要翻译：本发明涉及载脂蛋白Al-Milano（Apo Al-M / Apo Al-M）的基本上纯的二聚体，其首次已经从血浆中分离和表征。它还涉及包含Apo Al-M / Apo Al-M的药物组合物。载脂蛋白A1-M二聚体已经在重组大肠杆菌系统中产生，或者从载脂蛋白Al-Milano载体的血浆中收集。本发明还包括治疗动脉粥样硬化和心血管疾病的方法和二聚体在制备药物中的用途。含有二聚体的药物可用于动脉粥样硬化和心血管疾病的治疗，以及在动脉和静脉水平的不同临床情况下预防血栓形成。二聚体也可以作为单体的前药。

7. 发明申请

WO1992019256A1 NEW MEDICINAL USE 审中-公开
标题翻译：新药用途
公开(公告)号：WO1992019256A1
公开(公告)日：1992-11-12
申请号：PCT/SE1992000275
申请日：1992-04-27
申请人： KABI PHARMACIA AB , LAKE, Mats , SKOTTNER, Anna , KANJE, Martin
发明人： KABI PHARMACIA AB
IPC分类号： A61K37/02
CPC分类号： A61K38/30
摘要： The use of IGF-II for preparing a medicament for nerve regeneration; and a method for medical treatment resulting in nerve regeneration, comprising the step of administering to patient in need of such treatment an effective amount of IGF-II.
摘要翻译：使用IGF-II制备用于神经再生的药物; 以及导致神经再生的医疗处理方法，包括向需要这种治疗的患者施用有效量的IGF-II的步骤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式